Drug Profile
SCT 200
Alternative Names: Recombinant anti-EGFR monoclonal antibody - Sinocelltech; SCT-200Latest Information Update: 28 Mar 2023
Price :
$50
*
At a glance
- Originator Sinocelltech
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Breast cancer; Head and neck cancer
- Phase I/II Oesophageal cancer
- Phase I Squamous cell cancer
- No development reported Colorectal cancer
Most Recent Events
- 28 Mar 2023 No recent reports of development identified for phase-I development in Colorectal-cancer(Metastatic disease, Second-line therapy or greater) in China (Parenteral)
- 15 Jun 2022 Phase-I clinical trials in Squamous cell cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Recurrent) in China (IV) (NCT05552807)
- 04 Jun 2021 Efficacy and adverse events data from a phase Ib trial in Esophageal squamous cell carcinoma presented 57th Annual Meeting of the American Society of Clinical Oncology